Company Profile
Ascletis Pharma Inc., a biotechnology company provides the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company's commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure.
Its portfolio also includes ASC10 for treating respiratory syncytia virus, ASC10 and ASC11 to treat COVID-19, ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis, and ASC42 for the treatment of primary biliary cholangitis.
Additionally, it is developing ASC40 to treat recurrent glioblastoma. Its portfolio also includes ASC61 for advanced solid tumors, and ASC40, an oral small molecule for the treatment of acne, as well as ASC30, for obesity.
Its portfolio also includes ASC47 for muscle-preserving weight loss treatment, and ASC39, a potent and amylin-selective oral small molecule amylin receptor agonist. Founded in 2013, Ascletis Pharma is based in Wan Chai, Hong Kong.